3. Revlimid

Revlimid bottle
Revlimid was the centerpiece of Bristol Myers Squibb's $74 billion Celgene merger. (Bristol Myers Squibb)

Revlimid
Company: Bristol Myers Squibb
2019 sales: $11.11 billion
Projected 2026 sales: N/A
Projected CAGR: N/A
Used for: multiple myeloma, mantle cell lymphoma

When Bristol Myers Squibb completed its $74 billion megatakeover of Celgene late last year, one of the centerpieces of the deal was multiple myeloma blockbuster Revlimid. And now, with a troubling patent challenge off the books, the drug could just keep on growing. 

Revlimid nabbed $11.11 billion in sales in 2019, ranking it among pharma's elite sellers. Because Bristol closed its acquisition of Celgene in November, Evaluate did not forecast what 2026 sales could look like, but a lack of generics challengers and just two other biologics on the market could easily spell a sales bump in the coming years. 

Revlimid for years was known for its aggressive price hikes that caught flack from consumers and politicians but has mostly escaped unscathed on its march to blockbuster sales. 

Celgene escaped a spooky patent challenge last year from Alvogen that put a temporary damper on Bristol investors' hopes in the merger. But with that challenge off the table, Revlimid is in the clear to keep pursuing growth under its new parent company. 

RELATED: BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

3. Revlimid

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.